Targeting DNMT1 augments anti-tumor CD8⁺ T cell function
Maya G. DeshmukhiD, Danielle K. SohaiiD, Kamal ObbadiD, Koonam ParkiD, Simon MiletteiD, Peili Gu, Henna S. Nam, Andrew J. DanielsiD, Krasimir A. SpasoviD, Michael E. HurwitziD, Samuel G. KatziD, Richard Anthony FlavelliD, Karen S. AndersoniD, Marcus BosenbergiD, Goran MiceviciD
Abstract
Chronic stimulation of CD8 T cells within the tumor microenvironment (TME) induces a hypofunctional state characterized by diminished cytotoxicity and functionally impaired anti-tumor function, known as exhaustion. Exhaustion is associated with epigenetic changes that remain relatively stable despite interventions like immune checkpoint inhibition (ICI). Although epigenetic changes are potentially reversible, reports of therapeutic strategies to effectively restore function in exhausted CD8 T cells remain limited. Here, we report DNA methyltransferase 1 (DNMT1) inhibition (DNMT1i) in counteracting CD8+ T cell dysfunction during the anti-tumor response. We show that DNMT1i synergizes with ICI to rescue the tumor cell killing activity of chronically stimulated CD8 T cells in a melanoma model. DNMT1i mitigates transcriptional features of exhaustion while inducing a divergent effector program. DNMT1i attenuates the global increase in chromatin accessibility associated with exhaustion and enables epigenetic remodeling of the exhausted chromatin landscape upon restimulation. Finally, DNMT1i enhances the effector function of melanoma patient-derived tumor infiltrating lymphocytes after prolonged ex vivo expansion. These studies establish DNMT1 targeting as a promising strategy to counteract CD8 T cell exhaustion and potentiate ICI efficacy.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- ME1 Programs Latent Effector Capacity and Grounds a Mathematical Model of Reversible T Cell Exhaustion
Aubrey Y. Liew, Ying Li, … Haidong Dong·bioRxiv·May 10, 2026
- Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy
Or‐Yam Revach, Angelina M. Cicerchia, … Russell William Jenkins·Cell Reports MedicinePeer-reviewed·Jun 27, 2025
- PD-1 blockade during T cell priming enhances long-term protection against metastatic tumors by epigenetically tuning T cell exhaustion
Teresa Dinter, Sebastian D. Mackowiak, … Stefani Spranger·bioRxiv·Nov 25, 2025
- PD-1 prelimits both the cytotoxic and exhaustion potential in thymic CD8+ T cells and impacts the maintenance of peripheral tumor immunity
Zhiming Mao, Jacob B. Hirdler, … Haidong Dong·bioRxiv·Jan 18, 2025
- Dual-inactivation of Regnase-1 and SOCS1 rewires exhausted CD8+ T cell fate to enhance anti-tumor functionality
Isabelle Le Mercier, David Monteiro, … Micah J. Benson·bioRxiv·Jan 23, 2026
- DNA-Demethylating Agents enhance cytolytic activity of CD8+ T Cells and anti-tumor immunity
Helen Loo Yau, Ankur Chakravarthy, … Daniel D. De Carvalho·bioRxiv·Oct 2, 2017